Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
18.56
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
Next >
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...
Via
PressReach
Exposures
Product Safety
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
July 31, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
July 25, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
July 18, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
July 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
June 28, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
June 25, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
June 24, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
What is a Bull Flag Pattern? Explanation and Examples
June 13, 2024
Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends.
Via
MarketBeat
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
June 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
June 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
2 Generic Drug Makers With Growing Runways
May 31, 2024
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
May 29, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Alvotech
Via
GlobeNewswire
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
May 15, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
May 10, 2024
Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results.
Via
MarketBeat
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
May 08, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 08, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 2024 Bank of America Healthcare Conference
May 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
May 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
April 11, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
April 09, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.